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Objectives The aim of this study was to identify the remodeling parameters cardiomyocyte (CM) damage or death, hypertro-
phy, and fibrosis that may be linked to outcomes in patients with advanced heart failure (HF) in an effort to un-
derstand the pathogenic mechanisms of HF that may support newer therapeutic modalities.
Background There are controversial results on the influence of fibrosis, CM hypertrophy, and apoptosis on outcomes in pa-
tients with HF; other modalities of cell damage have been poorly investigated.
Methods In endomyocardial biopsy specimens from 100 patients with idiopathic dilated cardiomyopathy and advanced
HF, CM diameter and the extent of fibrosis were determined by morphometry. The proportion of CMs with evi-
dence of apoptosis, autophagic vacuolization (AuV), and oncosis was investigated by immunohistochemical
methods and by terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick end labeling.
Those parameters were correlated with mortality in 3 years of follow-up by univariate analysis and with multivar-
iate models incorporating the clinical variables more relevant to the prediction of outcomes.
Results CM AuV occurred in 28 patients (0.013  0.012%) and oncosis in 41 (0.109  0.139%). Nineteen patients
showed both markers. Apoptotic CM nuclei were observed in 3 patients. In univariate analysis, CM diameter and
AuV, either alone or associated with oncosis, were predictors of mortality. In multivariate analysis, CM diameter
(hazard ratio: 1.37; 95% confidence interval: 1.12 to 1.68; p  0.002) and simultaneous presence in the same
endomyocardial biopsy specimen of AuV and oncosis (hazard ratio: 2.82; 95% confidence interval: 1.12 to 7.13;
p  0.028) were independent predictors of mortality.
Conclusions CM hypertrophy and AuV, especially in association with oncosis, are predictors of outcome in patients with idio-
pathic dilated cardiomyopathy and severe HF. (J Am Coll Cardiol 2011;57:1523–31) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.080Heart failure (HF) has become the dominant cardiovascular
disorder in the Western world (1). Cardiac remodeling is
implicated in the development and progression of HF (2).
Among the 3 decisive components of remodeling, fibrosis,
cardiomyocyte (CM) hypertrophy, and damage (3), cell
death with deficient regeneration is considered 1 of the key
events for the occurrence of failure (4). Although the 3
classical mechanisms of cell death, apoptosis, necrosis, and
From the *Department of Pathology, University Hospital Favaloro Foundation,
Buenos Aires, Argentina; and the †Department of Intrathoracic Transplant, Univer-
sity Hospital Favaloro Foundation, Buenos Aires, Argentina. All authors have
reported that they have no relationships to disclose.Manuscript received July 5, 2010; revised manuscript received September 8, 2010,
accepted September 14, 2010.autophagy (5) have been reported to operate in failing
human hearts (6), current data do not allow determination
which is more relevant to the progression of HF and death.
See page 1532
To understand the pathogenic mechanisms of HF that may
support newer therapeutic modalities designed to act upon
remodeling, we investigated in endomyocardial biopsy (EMB)
specimens of patients with idiopathic dilated cardiomyopathy
(IDCM) and severe HF the relation between CM apoptosis,
oncosis, and autophagy and structural alterations of remodeling
(fibrosis and CM hypertrophy) with functional ventricular param-
eters with the aim of determining which is related to prognosis.
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the simultaneous presence of
CM autophagic vacuolization
(AuV) and oncosis and the mag-
nitude of CM hypertrophy are
strong independent predictors of
death in patients with IDCM
and advanced HF.
Methods
Study group. We studied retro-
spectively 100 consecutive pa-
tients with chronic HF referred
to the Heart Failure Center of
the University Hospital Favaloro
Foundation between September
1992 and September 2002 as po-
tential candidates for heart trans-
plantation (HT), who met the
diagnosis criteria for IDCM, de-
fined as ventricular chamber en-
largement, normal wall thickness,
and systolic dysfunction with left
ventricular ejection fraction (LVEF)
30% in the absence of coronary
artery disease as assessed by cor-
onary arteriography (7).
Patients with congenital, isch-
emic, or valvular heart disease,
severe arterial hypertension, his-
tological myocarditis and Cha-
gas’ heart disease were excluded.
ICDM was familiar in 8 patients and sporadic in 92
patients.
The local research ethics committee approved the study
protocol, and all patients gave written informed consent for
the EMB procedure.
In all patients, 12-lead electrocardiography, digital
24-h Holter monitoring, chest X-ray, M-mode and
bidimensional echocardiography, color Doppler, radio-
isotope ventriculography, right and left catheterization
with coronary angiography, EMB, and routine laboratory
analysis were performed. LVEF was determined by
radionuclide ventriculography.
Clinical status permitted the determination of peak oxy-
gen consumption (VO2max) in 76 patients and the 6-min
walking distance in 63 patients.
Tissue processing and morphometry. EMB samples from
the right ventricular septum were obtained using a Schultz-
Caves bioptome. The EMB tissue samples (mean 8.86 2.76
fragments) were fixed for 4 h in 10% buffered formaldehyde
and embedded in paraffin. The tissue blocks were kept at 4°C
and processed simultaneously for the immunohistochemical
studies. Tissue sections 3 m thick were stained with hema-
Abbreviations
and Acronyms
AuV  autophagic
vacuolization
C9  complement factor 9
CM  cardiomyocyte
CMD  cardiomyocyte
diameter
EMB  endomyocardial
biopsy
HF  heart failure
HT  heart transplantation
IDCM  idiopathic dilated
cardiomyopathy
IQR  interquartile range
LASD  left atrial systolic
diameter
LVEDD  left ventricular
end-diastolic diameter
LVEF  left ventricular
ejection fraction
PAWP  pulmonary artery
wedge pressure
TUNEL  terminal
deoxynucleotidyl
transferase–mediated
deoxyuridine triphosphate
nick end labeling
VO2max  peak oxygen
consumption
VT  ventricular
tachycardiaoxylin and eosin, trichrome, and Picrosirius red. cMaximal cardiomyocyte diameter (CMD) was deter-
ined using a digital analysis system (Image Pro Plus 4.5,
edia Cybernetics, Silver Spring, Maryland) in 200 cells
ransversally sectioned at the nuclear level.
Interstitial fibrosis was expressed as the percent of Picro-
irius red–positive areas respective to the whole area of the
MB sample, excluding the endocardium, scanned using
he same digital analysis system.
nvestigation of apoptosis, oncosis, and autophagy. Tis-
ue sections were rehydrated and incubated with monoclo-
al antibodies against ubiquitin and Beclin-1 for determi-
ation of autophagy, and anti-complement factor 9 (C9) for
ncosis (Novocastra, Newcastle-on-Tyne, United King-
om). The specificity of all antibodies was verified by
mission of primary antibodies. The secondary detection
ystem was a commercial kit (Biogenex, San Ramon, Cali-
ornia) with biotinylated antimouse immunoglobulin G,
eroxidase-linked streptavidin, and AEC (3-amino-9-ethyl
arbazole) as chromogen. In addition, in selected EMB
pecimens, double labeling studies were carried out with
ntiubiquitin and anti-Beclin-1 antibodies using a commer-
ial kit (ABC, Vector, Burlingame, California) and
uorescein-labeled and Texas red–labeled streptavidin. Ob-
ervations were made with a 100 ultraviolet lamp and
hotographed with an AXIOCAM camera (Carl Zeiss AG,
berkochen, Germany). Apoptosis was investigated using
he terminal deoxynucleotidyl transferase–mediated deoxy-
ridine triphosphate nick end labeling (TUNEL) method
ith a commercial kit (CardioTACS, R&D Systems, Min-
eapolis, Minnesota).
The proportion of cells labeled with the markers was
elated to the number of CM nuclei present in the whole
issue section.
To determine the number of CM nuclei present in each
MB specimen, the area of the tissue sections, after
limination of the endocardial fibrotic area, was determined
n images collected at 4 magnification with a commercial
igital scanner using a digital analysis system (Image Pro
lus 4.5). The number of CM nuclei (mean 344  112)
resent in 1 mm2 was determined on randomly chosen areas
t 400 magnification. From these data and the area of the
issue section, positive cells were expressed as a percent of
he total number of CM nuclei. In addition, results were
ichotomized as negative or positive when at least 1 CM
ytoplasm for the determination of AuV and oncosis, or 1
M nucleus for apoptosis, was stained with the markers.
The study was carried out under Nomarski optics. CMs
ere identified by the presence of sarcomeres and by their
ize and shape.
Studies were carried out on a single-blind basis, and
esults were included in the patient database after data from
00 biopsies were collected.
ollow-up. We observed patients until death or HT or
ntil September 2005, beginning at the time of baseline
ardiac catheterization and EMB.
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bulatory visits and by telephone contact with patients or
their physicians.
The end point was all-cause mortality. Deaths were
classified as sudden death, HF death, noncardiovascular
death, or unknown. HT, either United Network for Organ
Sharing status 1 or 2, was coded as a nonfatal end point, and
patient follow-up was censored at the time of transplanta-
tion. Patients lost to follow-up were also censored at the
time of last known alive-and-well date.
Statistical analysis. Continuous variables are reported as
mean  SD or median (interquartile range [IQR]), and
categorical variables are presented as percents of all patients.
Differences between continuous variables were assessed using
Student t tests or Mann-Whitney U tests as applicable.
hi-square or Fisher exact tests were used to compare cate-
orical variables. The relationship between EMB parameters
nd clinical variables was studied using Pearson’s correlation
oefficient. Univariate Cox regression analysis was performed
o identify predictors of all-cause mortality. Clinical variables
hat on univariate analysis had p values0.05 were included in
he multivariate models with the EMB parameters that also
ad p values 0.05. When 2 or more selected variables were
losely associated (correlation coefficient 0.600), the variable
hosen was that with the greatest Wald statistic.
Kaplan-Meier survival curves were calculated with the
ata dichotomized at the mean value for each parameter,
nd a comparison of groups was made using the log-rank
est. Two-sided p values 0.05 were considered significant.
tatistical analysis was performed using SPSS version 11.0
SPSS, Inc., Chicago, Illinois).
esults
atient characteristics. One hundred patients (59 men,
ean age 42.48  15.38 years) with IDCM and chronic HF
ere analyzed. Most patients (83%) were in New York Heart
ssociation functional classes III and IV, and 17 were in classes
and II at the moment of evaluation, when baseline cardiac
atheterization and EMB were performed. The mean LVEF
as 20.8  7.41%. Three patients had histories of sustained
entricular tachycardia (VT). In 24-h Holter recordings, 48
atients presented complex ventricular arrhythmias, 33 patients
howed nonsustained VT, and 15 patients showed ventricular
remature contractions of Lown grade 4A (couplets). Echo-
ardiographic studies showed moderate to intense dilation of
he cavities: the mean left ventricular end-diastolic diameter
LVEDD) was 73.6 mm, and the mean left atrial systolic
iameter (LASD) was 47.5 mm (Table 1).
All patients received conventional medical treatment for HF.
orphometric studies. CM HYPERTROPHY AND FIBROSIS.
The mean CMD was 17.7  2.55 m, and all patients
showed variable degrees of interstitial fibrosis (mean 14.27 
7.34%) (Fig. 1A).APOPTOSIS AND ONCOSIS. Apoptotic CM nuclei stained
using the TUNEL method were infrequently observed (in
only 4 nuclei in 3 patients) (Fig. 1B).
Staining of the CM cytoplasm with the anti-C9 antibody
was usually diffuse (Fig. 1C), with occasional peripheral
localization, and was present in 41 patients.
The number of C9-positive CMs varied between 1 and
17, representing 0.109  0.139% of the whole nuclei
examined.
AUTOPHAGY. The criterion for defining AuV was the pres-
ence of CMs with large cytoplasm vacuoles containing
ubiquitin-positive material (Figs. 1D and 1E). We did not
consider CMs with ubiquitin-stained nuclei or small gran-
ular cytosolic deposits (Fig. 1F). In addition, we investi-
gated Beclin-1 as a second marker of autophagy. In all
ubiquitin-positive CMs, we observed colocalization of
Beclin-1 in the same cell, although the pattern of distribu-
tion was slightly different (Figs. 1G to 1J).
CMs with evidence of AuV were observed in 28 patients.
In the positive EMB samples, the number of CMs with
AuV ranged between 1 and 18, representing 0.013 
0.012% of the whole nuclei examined.
SIMULTANEOUS PRESENCE OF ONCOSIS AND AUTOPHAGY.
Nineteen patients showed the simultaneous presence of
oncosis and AuV, although in different cells.
Correlation between clinical and EMB parameters. CMD.
CMD was associated with sex (18.1  2.6 m in men vs.
7.1  2.3 m in women, p  0.04) and New York Heart
ssociation functional class (16.4  2.1 m in patients in
lasses I and II vs. 18.0  2.6 m in patients in classes III
and IV, p  0.02). Statistical analysis showed negative
correlations of CMD with VO2max (r  0.353, p  0.002),
LVEF (r  0.335, p  0.001), cardiac index (r  0.356,
 0.001), systolic blood pressure (r  0.220, p  0.03),
and diastolic blood pressure (r  0.264, p  0.008).
Positive correlations were found between CMD and
mean pulmonary artery pressure (r  0.448, p  0.001),
PAWP (r  0.387, p  0.001), LVEDD (r  0.283, p 
.004), left ventricular end-systolic diameter (r  0.216,
p  0.036), and LASD (r  0.276, p  0.006).
INTERSTITIAL FIBROSIS. Fibrosis was associated with
NYHA functional class (10.8  3.9% vs. 15.0  7.7% in
atients in classes I and II vs. classes III and IV, p  0.002)
nd with the presence of VT (16.5  8.6% vs. 13.0  6.3%
n patients with and without VT, p  0.019). Negative
orrelations were found between interstitial fibrosis and
O2max (r  0.283, p  0.013) and cardiac index (r 
0.249, p  0.017). A positive correlation was found with
mean pulmonary artery pressure (r  0.220, p  0.034).
APOPTOSIS. We did not incorporate data obtained with the
TUNEL method because only 4 apoptotic CM nuclei were
observed in 3 EMB specimens from 3 different patients.
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was associated with VO2max (15.4  4.5 ml/kg/min vs. 18.3 
.9 ml/kg/min, p  0.024), LASD (50.6  8.6 mm vs. 45.4 
.5 mm, p 0.006), and VT (20 of 36 vs. 21 of 64 C9-positive
MB samples in patients with and without VT, p  0.03).
AUTOPHAGY. AuV was associated only with VT (17 of 36
vs. 11 of 64 EMB samples with AuV in patients with and
without VT, p  0.001). AuV was also associated with
oncosis (p  0.003).
SIMULTANEOUS PRESENCE OF AUTOPHAGY AND ONCOSIS.
The presence of AuV and C9 positivity in the same EMB
specimen was associated with VO2max (13.4 4.2 ml/kg/min vs.
Baseline Characteristics and Outcomes of 100Table 1 Baseline Characteristics and Outco
Variable
Total Popula
(n  100
Demographic parameters
Age (yrs) 42.5 15
Men 59 (59%
Functional parameters
NYHA functional class III and IV 83 (83%
6-min walking distance (m) (n  63) 341 69
VO2max (ml/kg/min) (n  76) 17.0 5.
Ventricular function
LVEF (%) 20.8 7.
MR (moderate to severe) 53 (53%
Hemodynamic parameters
Cardiac index (l/min/m2) 2.46 0.
SBP (mm Hg) 102 18
DBP (mm Hg) 62.4 11
Mean PAP (mm Hg) 23.5 10
PAWP (mm Hg) 15.9 8.
Right atrial pressure (mm Hg) 5.89 4.
Electrophysiological parameters
Heart rate (beats/min) 87.2 16
Left bundle branch block 57 (57%
Atrial fibrillation 15 (15%
VT 36 (36%
Echocardiographic parameters (mm)
LVEDD 73.6 10
LVESD 62.1 11
LASD 47.5 9.
EMB morphometry
CMD (m) 17.7 2.
Interstitial fibrosis (%) 14.3 7.
EMB cardiomyocyte damage or death
AuV 28 (28%
AuV, quantitative 0 (0–1)
Oncosis (C9 positive) 41 (41%
C9 positive, quantitative 0 (0–2)
AuV plus oncosis 19 (19%
Data are expressed as mean  SD, n (%), or median (interquartile ra
AuV  autophagic vacuolization; CMD  cardiomyocyte diamete
endomyocardial biopsy; IDCM  idiopathic dilated cardiomyopathy;
diameter; LVEF  left ventricular ejection fraction; LVESD  left ventricu
Association; PAP  pulmonary artery pressure; PAWP  pulmonary a
consumption; VT  ventricular tachycardia.8.0 5.4 ml/kg/min, p  0.003), LASD (51.8  9.1 mm ts. 46.5  9.3 mm, p  0.028), and VT (15 of 36 patients
ith VT vs. 4 of 64 patients without VT, p  0.01) in
atients with and without both markers, respectively.
CMD, fibrosis, oncosis, and AuV were not correlated
ith the remaining clinical parameters selected for the
tudy. CMD and fibrosis did not show correlations among
hem and with oncosis and AuV.
utcomes. A total of 27 deaths were recorded, 13 attributable
o progressive HF, 8 to sudden cardiac death, and 3 to noncardiac
auses. In 3 patients, the cause of death could not be determined.
welve patients underwent urgent HT and 16 underwent elective
T. Four patients were lost to follow-up.
The median time of follow-up was 3.1 years (IQR: 0.6
nts With IDCMof 100 Patients With IDCM
All-Cause Death
(n  27)
Survivors
(n  73) p Value
43.4 16.0 42.1 15.3 0.727
20 (74.1%) 39 (53.4%) 0.062
24 (88.9%) 59 (80.8%) 0.549
315 75.2 349 66.2 0.107
15.9 4.21 17.4 5.84 0.306
20.8 8.44 20.8 7.07 0.978
18 (66.7%) 35 (47.9%) 0.096
2.29 0.83 2.51 0.79 0.263
98.1 14.2 104 19.5 0.157
59.7 10.4 63.3 11.9 0.177
30.0 11.9 21.3 9.18 0.001
21.6 8.97 14.0 7.59 0.001
7.00 4.97 5.51 4.46 0.182
89.4 18.2 86.4 16.0 0.456
15 (55.6%) 42 (57.5%) 0.859
5 (18.5%) 10 (13.7%) 0.549
17 (63.0%) 19 (26.0%) 0.001
79.1 12.3 71.5 8.29 0.005
68.1 12.8 59.8 9.79 0.001
52.3 7.42 45.7 9.55 0.002
19.6 2.58 17.0 2.18 0.001
15.3 5.64 13.9 7.88 0.390
14 (51.9%) 14 (19.2%) 0.001
1 (0–5) 0 (0–0) 0.001
14 (51.9%) 27 (37%) 0.180
1 (0–3) 0 (0–2) 0.102
11 (40.7%) 8 (11%) 0.001
complement factor 9; DBP  diastolic blood pressure; EMB 
left atrial systolic diameter; LVEDD  left ventricular end-diastolic
-systolic diameter; MR  mitral regurgitation; NYHA  New York Heart
dge pressure; SBP  systolic blood pressure; VO2max  peak oxygenPatiemes
tion
)
.4
)
)
.1
49
41
)
80
.4
.6
.5
61
61
.6
)
)
)
.0
.2
45
55
34
)
)
)
nge).
r; C9 
LASD 
lar endo 5.3 years). The median follow-up of United Network
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(IQR: 0.1 to 0.3 years), of status 2 HT patients was 1.14
years (IQR: 0.3 to 2.6 years), and of surviving nontrans-
planted patients was 5.3 years (IQR: 4.0 to 7.6 years).
As can be seen in Table 1, many of the clinical parameters, the
magnitude of CMD, the presence of AuV, and the simultaneous
presence of AuV with oncosis showed correlations with outcomes.
Univariate analysis. On Cox regression analysis of the base-
line variables, the univariate clinical predictors of survival were
mitral regurgitation, systolic blood pressure, mean pulmonary
Figure 1 Images of Fibrosis, Apoptosis, Oncosis, and AuV
(A) Low-power view of an endomyocardial biopsy specimen showing staining of co
terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick en
ment factor 9, interpreted as evidence of oncosis. (D, E) Two CMs with large vacu
an antiubiquitin antibody. (F) CMs with smaller deposits of ubiquitin or nuclear sta
Successive tissue sections of the same CM incubated with antiubiquitin (G) and a
vacuole appears more abundant than the Beclin-1-positive material. (I, J) Doub
Beclin-1 antibodies and revealed with Texas red (ubiquitin, I) and fluorescein (B
positive deposit, which is located at the vacuole border. Scale bar: 100 m (Aartery pressure, PAWP, right atrial pressure, VT, LVEDD,left ventricular end-systolic diameter, and LASD. The struc-
tural predictors were CMD and the presence of AuV, either
alone or associated with oncosis in the same EMB specimen.
In contrast, the magnitude of fibrosis and the presence of
oncosis as the only modality of CM damage or death were not
predictors of outcomes (Table 2).
Multivariate analysis. Both CMD and the simultaneous
presence of AuV and oncosis were independent predictors
of mortality when they were incorporated in 2 base models
adjusted for the 2 strongest clinical predictor variables:
by Picrosirius red. (B) Apoptotic nuclei in 2 adjacent cardiomyocytes (CMs) on
ling. (C) Diffuse stain of the CM sarcoplasm with an antibody against comple-
xtending to most of the cell and containing material stained after incubation with
row) were not considered as undergoing autophagic vacuolization (AuV). (G, H)
clin-1 (H) antibodies. The ubiquitin-positive material contained within the large
unofluorescence stain of the same CM incubated with antiubiquitin and anti-
1, J). Within the large vacuole, there is more ubiquitin-positive than Beclin-1–
m (B, G, H), 10 m (C to F), 5 m (I, J).llagen
d labe
oles e
in (ar
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0.05 in the univariate analysis (Table 3).
Kaplan-Meier survival estimation. Kaplan-Meier survival
curves against all-cause mortality for LVEDD, PAWP,
CMD, and the simultaneous presence of AuV and oncosis
are shown in Figure 2.
iscussion
n this study, we correlated the magnitude of fibrosis, CM
ypertrophy, oncosis, and extensive AuV with mortality in
atients with advanced HF. Those parameters were found
o be associated with the 2 main causes of death, HF and
T. We used both univariate and multivariate models for
ur study, as it is known that in HF, most parameters that
Cox Regression Univariate Analysisfor All-Cau e DeathTable 2 Cox Regression Univariate Analysisfor All-Cause Death
Variable HR (95% CI) p Value
Age 1.00 (0.97–1.02) 0.889
Male 2.26 (0.95–5.39) 0.065
NYHA functional class III and IV 2.34 (0.70–7.83) 0.167
6-min walking distance 0.99 (0.99–1.00) 0.096
VO2max 0.93 (0.86–1.02) 0.128
LVEF 0.97 (0.92–1.03) 0.352
MR (moderate to severe) 2.43 (1.09–5.43) 0.030
Cardiac index 0.57 (0.28–1.15) 0.115
SBP 0.98 (0.96–1.00) 0.033
DBP 0.98 (0.95–1.01) 0.134
Mean PAP 1.07 (1.04–1.11) 0.001
PAWP 1.10 (1.06–1.15) 0.001
Right atrial pressure 1.12 (1.03–1.23) 0.012
Heart rate 1.02 (0.99–1.04) 0.209
Left bundle branch block 0.79 (0.37–1.68) 0.536
Atrial fibrillation 1.67 (0.63–4.45) 0.305
VT 3.25 (1.48–7.12) 0.003
LVEDD 1.10 (1.05–1.15) 0.001
LVESD 1.09 (1.05–1.13) 0.001
LASD 1.09 (1.04–1.15) 0.001
CMD 1.34 (1.19–1.53) 0.001
Interstitial fibrosis 1.02 (0.97–1.06) 0.433
AuV 2.97 (1.40–6.34) 0.005
Oncosis (C9 positive) 1.89 (0.88–4.04) 0.101
AuV plus oncosis 3.20 (1.48–6.94) 0.003
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.
Cox Regression Multivariate Analysis for All-CauTable 3 Cox Regression Multivariate Analys
Model HR (95%
Model 1 (PAWP  LVEDD) 1.31 (1.09–
Model 2 (model 1  MR) 1.30 (1.09–
Model 3 (model 1  MR  SBP) 1.32 (1.09–
Model 4 (model 1  MR  SBP  VT) 1.30 (1.08–
Model 5 (model 1  age  sex) 1.37 (1.13–
Model 6 (all covariates) 1.37 (1.12–Abbreviations as in Tables 1 and 2.have significant predictive value in univariate models do not
retain that value in multivariate regression analysis (8). The
main results were that the magnitude of CMD, the presence
of AuV, and the simultaneous occurrence of AuV and
oncosis in the same EMB specimen were predictors of
mortality.
Fibrosis and CMD as predictors of outcomes. Coinci-
dent with previous reports (9–11), the fractional area of
collagen was not associated with death. Recently, fibrosis,
determined by cardiovascular magnetic resonance, has been
linked to prognosis in dilated cardiomyopathy (12). This
discrepancy could be because in EMB, the study is limited
to the subendocardial area, and cardiovascular magnetic
resonance shows mesocardial fibrosis.
As opposed to fibrosis, CMD was an important indepen-
dent predictor of death. More than 50% of patients with
CMD over 17.7 m died during follow-up, compared with
about 10% of patients with CMD below 17.7 m. The few
tudies published in the past correlating CMD with out-
omes in patients with advanced HF have shown dissimilar
esults (9–11,13). More recent reports also claim that CMD
oes not correlate with outcomes in HF (14,15). This
iscrepancy with our results could be ascribed to the
ifferent origin of the EMB samples (left ventricle vs. right
entricle), to the small number of EMB fragments evaluated
1 vs. 8.6), to the smaller number of cells analyzed (50 vs.
00), and to the different end points considered (death or
T and major arrhythmic events during the follow-up vs.
eath) in 1 study (14) and to the smaller number of patients
ncluded in another study (35 vs. 100) (15). Moreover, in
hose studies, multivariate analysis was not performed.
ncosis and AuV as predictors of outcomes. Previous
eports have stressed the importance of apoptosis as a
omponent of HF (16) and have even proposed that its
agnitude is associated with outcomes (17). In our study,
he percent of TUNEL-positive nuclei was very small, in
greement with recent data from other studies (4,18–20).
his low frequency of apoptosis could be ascribed to the fact
hat our patients were in an advanced stage of HF, and it is
nown that in this condition, the proportion of apoptotic
Ms is very low or nil (21). For this reason, apoptotic cell
eath was not considered for the statistical analysis.
eathAll-Cause Death
AuV  Oncosis
p Value HR (95% CI) p Value
0.004 3.24 (1.39–7.52) 0.006
0.004 3.20 (1.38–7.44) 0.007
0.004 3.14 (1.33–7.45) 0.009
0.007 2.99 (1.20–7.47) 0.019
0.001 3.12 (1.34–7.27) 0.008
0.002 2.82 (1.12–7.13) 0.028se Dis for
CMD
CI)
1.57)
1.56)
1.59)
1.57)
1.67)
1.68)
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April 5, 2011:1523–31 Cell Size, Autophagy, and Oncosis Predict MortalityTo our knowledge, few studies exist on the presence of
oncosis in IDCM (6,18,20). The introduction of C9, a part
of the membrane attacking complex C5b-9, is currently
accepted as a tool for the detection of early oncosis (22). Our
observation that CMs with sarcoplasmic C9 were present in
41% of EMB specimens indicates that oncosis is frequent
and may play an important role in HF. In aortic stenosis,
the proportion of oncotic myocytes increases significantly
during progression to HF (4).
The presence of oncosis as the only modality of cell death
did not show a correlation with prognosis, but its association
Figure 2 Kaplan-Meier Curves Against All-Cause Mortality for C
Kaplan-Meier survival curves for left ventricular end-diastolic diameter (LVEDD) (A)
(CMD) (C), and autophagic vacuolization plus oncosis (D), stratified at greater thawith AuV was a strong independent predictor of mortality.Autophagy has been considered an adaptive mechanism
for degradation and recycling of cytoplasmic components,
such as long-lived proteins and organelles (23). In situ
demonstration of autophagy in the human heart has been
based on electron microscopy and the presence of large
deposits of ubiquitin in the myocytes (4,6,20).
In addition, we decided to use Beclin-1, a bcl-2–
interacting protein that promotes autophagy, as a second in
situ marker of autophagy. Increased levels of Beclin-1 were
elevated during cardiac injury induced by ischemia-
reperfusion (24) and down-regulated in failing human
l and EMB Parameters
onary artery wedge pressure (PAWP) (B), cardiomyocyte diameter
hed line) and less than (solid line) the mean value against all-cause mortality.linica
, pulm
n (dashearts after mechanical unloading (18).
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Cell Size, Autophagy, and Oncosis Predict Mortality April 5, 2011:1523–31The role of autophagy in cell death is controversial, and
most evidence suggests that is an adaptive response (25,26).
With the present evidence, it is not possible to state if the
presence of large deposits of ubiquitin or Beclin-1 contrib-
utes directly to cell death or represents a mechanism for its
prevention, as has been previously stated (27), but it appears
reasonable to suppose that CMs with extensive loss of
organelles and sarcomeres, although they may not be dead,
are unable to produce a significant amount of contractile
power, to contributing to a worsening of cardiac function
and HF (28). In the literature, large deposits or extensive
vacuolization has been termed autophagic cell death
(4,6,20). However, we prefer to use the term “autophagic
vacuolization,” as has been recently recommended (29),
because it is not definitely known if those cells are really
dead. The role of autophagy in HF probably depends on the
severity of HF. It has been reported that in cardiac hypertrophy
and in the transition to HF, autophagy may be beneficial, but
above a certain threshold, autophagic activity might lead to HF
(26,27). This is supported by the presence of increased ubiqui-
tinated proteins in failing human hearts (6,30).
Evidence of AuV was present in 28% of EMB specimens.
Autophagy has been observed in dilated cardiomyopathy,
and in terminal HF, 0.08% to 0.34% of CMs of left
ventricular sections in explanted hearts showed sarcoplasmic
ubiquitin inclusions (6,20).
Although in our study, AuV was a significant predictor of
death in the univariate analysis, in the multivariate analysis,
its statistical value was not retained. However, AuV was a
strong predictor of outcome when associated with oncosis in
the same EMB specimen. This observation suggests that
both modalities of cell damage may be relevant for the
progressive functional deterioration of the heart that ends in
death.
Study limitations. The main limitations of our study are
that it was an observational and retrospective analysis of data
that were generated for clinical purposes and not prospec-
tively, the relatively small number of patients, and the small
size of tissue samples on EMB. Although it is known that
right ventricular EMB specimens are representative of the
state of the myocardium when a sufficient number (more
than 5 samples) have been obtained (31), and quantitative
representation of cell death in EMB specimens mirrors that
in the whole heart (32), and thus it can be assumed that
oncosis and AuV are diffuse processes, the possibility of an
underestimation of the proportion of CMs with evidence of
oncosis and AuV should be considered. As a consequence of
the small number of events, most of the multivariate models
presented were overfitted. Such models may capitalize on
the particular characteristics of the sample, and thus our
findings may not be consistent on replication.
Conclusions
Our results, stressing that CM hypertrophy and cell damage
by AuV, especially when associated with oncosis, are inde-pendent predictors of death in patients with IDCM and
advanced HF, not only give support to the established
opinion that remodeling is an important component of HF
but indicate that in a population of patients with IDCM
and advanced HF, the magnitude of those phenomena—the
greater the extent of CM hypertrophy and cell damage, the
poorer the prognosis—is related with outcome and suggests
that to modify the ominous prognosis of patients with
advanced HF, prevention or reversal of CM hypertrophy
(33,34) and cell damage by AuV and oncosis (35) should
become major targets for therapeutic intervention in heart
pathophysiology.
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